Corporate News
2024
Posting of Annual Report and Notice of Annual General Meeting
05 June 2024
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, confirms that the Annual Report and Accounts for the year ended 31 December 2023 and the Notice of Annual General Meeting (“AGM”) have been posted to shareholders.
A copy of the 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy is now available to download from the Company website in accordance with AIM Rule 20: investors.genincode.com/investors
The AGM will be held in person at the offices of Cavendish Capital Markets, One Bartholomew Close, London, EC1A 7BL on Thursday 27 June 2024 at 2.00 p.m.
For more information visit www.genincode.com
Enquiries:
| GENinCode Plc | www.genincode.com or via Walbrook PR | |
| Matthew Walls, CEO | ||
| Paul Foulger, CFO | ||
| Cavendish Capital Markets Limited | Tel: +44 (0)20 7397 8900 | |
| Giles Balleny / Dan Hodkinson (Corporate Finance) | ||
| Nigel Birks / Harriet Ward (Corporate Broking) | ||
| Dale Bellis / Michael Johnson (Sales) | ||
| Walbrook PR Limited Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage | Tel: 020 7933 8780 or [email protected] | |
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease and ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.
2023
Posting of Annual Report and Notice of Annual General Meeting
05 June 2024
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, confirms that the Annual Report and Accounts for the year ended 31 December 2023 and the Notice of Annual General Meeting (“AGM”) have been posted to shareholders.
A copy of the 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy is now available to download from the Company website in accordance with AIM Rule 20: investors.genincode.com/investors
The AGM will be held in person at the offices of Cavendish Capital Markets, One Bartholomew Close, London, EC1A 7BL on Thursday 27 June 2024 at 2.00 p.m.
For more information visit www.genincode.com
Enquiries:
| GENinCode Plc | www.genincode.com or via Walbrook PR | |
| Matthew Walls, CEO | ||
| Paul Foulger, CFO | ||
| Cavendish Capital Markets Limited | Tel: +44 (0)20 7397 8900 | |
| Giles Balleny / Dan Hodkinson (Corporate Finance) | ||
| Nigel Birks / Harriet Ward (Corporate Broking) | ||
| Dale Bellis / Michael Johnson (Sales) | ||
| Walbrook PR Limited Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage | Tel: 020 7933 8780 or [email protected] | |
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease and ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.
2022
Posting of Annual Report and Notice of Annual General Meeting
05 June 2024
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, confirms that the Annual Report and Accounts for the year ended 31 December 2023 and the Notice of Annual General Meeting (“AGM”) have been posted to shareholders.
A copy of the 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy is now available to download from the Company website in accordance with AIM Rule 20: investors.genincode.com/investors
The AGM will be held in person at the offices of Cavendish Capital Markets, One Bartholomew Close, London, EC1A 7BL on Thursday 27 June 2024 at 2.00 p.m.
For more information visit www.genincode.com
Enquiries:
| GENinCode Plc | www.genincode.com or via Walbrook PR | |
| Matthew Walls, CEO | ||
| Paul Foulger, CFO | ||
| Cavendish Capital Markets Limited | Tel: +44 (0)20 7397 8900 | |
| Giles Balleny / Dan Hodkinson (Corporate Finance) | ||
| Nigel Birks / Harriet Ward (Corporate Broking) | ||
| Dale Bellis / Michael Johnson (Sales) | ||
| Walbrook PR Limited Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage | Tel: 020 7933 8780 or [email protected] | |
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease and ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.
2021
Posting of Annual Report and Notice of Annual General Meeting
05 June 2024
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, confirms that the Annual Report and Accounts for the year ended 31 December 2023 and the Notice of Annual General Meeting (“AGM”) have been posted to shareholders.
A copy of the 2023 Annual Report and Accounts, the Notice of AGM and accompanying form of proxy is now available to download from the Company website in accordance with AIM Rule 20: investors.genincode.com/investors
The AGM will be held in person at the offices of Cavendish Capital Markets, One Bartholomew Close, London, EC1A 7BL on Thursday 27 June 2024 at 2.00 p.m.
For more information visit www.genincode.com
Enquiries:
| GENinCode Plc | www.genincode.com or via Walbrook PR | |
| Matthew Walls, CEO | ||
| Paul Foulger, CFO | ||
| Cavendish Capital Markets Limited | Tel: +44 (0)20 7397 8900 | |
| Giles Balleny / Dan Hodkinson (Corporate Finance) | ||
| Nigel Birks / Harriet Ward (Corporate Broking) | ||
| Dale Bellis / Michael Johnson (Sales) | ||
| Walbrook PR Limited Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage | Tel: 020 7933 8780 or [email protected] | |
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease and ovarian cancer. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer.